

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Leader Ventures, LLC		08/08/2012	LIMITED LIABILITY COMPANY: DELAWARE
RECEIVING PARTY DATA			
Name:	XDx, Inc.		
Street Address:	3260 Bayshore Blvd.		
City:	Brisbane		
State/Country:	CALIFORNIA		
Postal Code:	94005		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 6			
Property Type	Number	Word Mark	
Serial Number:	78353208	ALLOMAP	
Serial Number:	78516396	ALLOMAP	
Serial Number:	78516400	XDX EXPRESSION DIAGNOSTICS	
Serial Number:	78516406	XDX	
Serial Number:	78977275	XDX	
Serial Number:	78438424	XDX EXPRESSION DIAGNOSTICS	
CORRESPONDENCE DATA			
Fax Number:	6504936811		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	650-496-7543		
Email:	nbouch@wsgr.com		
Correspondent Name:	WSGR, c/o Nancy Bouch, Senior Paralegal		
Address Line 1:	650 Page Mill Road		
Address Line 2:	FH 2-1 P10		

CH \$165.00 78353208

Address Line 4: Palo Alto, CALIFORNIA 94304

ATTORNEY DOCKET NUMBER:	22077.040
NAME OF SUBMITTER:	Nancy Bouch
Signature:	/s/Nancy Bouch
Date:	08/09/2012

Total Attachments: 33

source=XDx - Leader Ventures - IP Termination and Release (executed)#page1.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page2.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page3.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page4.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page5.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page6.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page7.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page8.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page9.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page10.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page11.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page12.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page13.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page14.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page15.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page16.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page17.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page18.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page19.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page20.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page21.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page22.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page23.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page24.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page25.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page26.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page27.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page28.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page29.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page30.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page31.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page32.tif
source=XDx - Leader Ventures - IP Termination and Release (executed)#page33.tif

**TERMINATION OF SECURITY INTEREST IN
INTELLECTUAL PROPERTY**

THIS TERMINATION OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (the "Termination"), dated as of August 8, 2012, is executed by Leader Ventures, LLC ("Agent"), in favor of XDx, Inc., a Delaware corporation (together with its successors and assigns, "Debtor") located at 3260 Bayshore Blvd., Brisbane, CA 94005. Capitalized terms used herein have the meaning assigned in the Growth Capital Loan and Security Agreement, dated as of August 27, 2009.

Recitals

A. In connection with that certain Growth Capital Loan and Security Agreement, dated as of August 27, 2009 (as amended from time to time, the "Loan and Security Agreement"), executed by Debtor in favor of Agent on behalf of the entities set forth on Schedule 3 thereto, Debtor and Agent entered into an Intellectual Property Security Agreement, dated as of August 27, 2009 (the "Agreement"), wherein Debtor granted to Agent a security interest in the Collateral. The Collateral included, without limitation, all Intellectual Property of the Debtor.

B. The Agreement was recorded with the Patent Division of the United States Patent and Trademark Office on August 31, 2009, at Reel/Frame 023163/0695 to evidence the security interest granted under the Loan and Security Agreement.

C. The Agreement was recorded with the Trademark Division of the United States Patent and Trademark Office on August 31, 2009, at Reel/Frame 4054/0595 to evidence the security interest granted under the Loan and Security Agreement.

D. Debtor has satisfied in full the Secured Obligations (as defined in the Loan and Security Agreement) under and secured by the Loan and Security Agreement and Agent has agreed to terminate and release its security interest in the Copyrights, Patents and Trademarks (as defined below) as herein provided.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Agent expressly terminates and releases its security interest in, to and under the following (collectively, the "Copyrights", "Patents" and "Trademarks"):

a. all Patents, together with any reissue, continuation, continuation-in-part or extension thereof, and all proceeds thereof, including any and all causes of action which may exist by reason of infringement thereof for the full term of the Patents, including the Patents listed on Schedule A hereto ;

b. all Trademarks, together with the goodwill of the business symbolized by the Trademarks and the customer lists and records related to the Trademarks and the applications and registrations thereof, and all proceeds thereof, including any and all causes of action which may exist by reason of infringement thereof, including the Trademarks listed on Schedule B hereto;


c. all Copyrights and the registrations thereof, together with any renewals or extensions thereof, and all proceeds thereof, including any and all causes of action which may exist by reason of infringement thereof for the full term of the Copyrights, including the Copyrights listed on Schedule C hereto;

Agent authorizes and requests that the Commissioner for Patents and Trademarks and any other governmental officer record this Termination.

[Signature Page Follows]

IN WITNESS WHEREOF, Lender has executed and delivered this Termination as of the day and year first above written.

LEADER VENTURES, LLC


Name: ROBERT W. MOLKE
Title: MANAGING DIRECTOR

SCHEDULE A

PATENTS

Patent Status Report for XDX, Inc.
 Client Number: 50661
 August 26, 2009

ATTY REF # CLIREF #	COUNTRY	TITLE	APP # FILE DATE	PATENT # GRANT DATE	PARENT # FILE DATE	FILE TYPE	INVENTOR(S)	OWNER	STATUS SUBSTATUS NEXT TAX	PENDING ACTIONS ACTION DUE DATE
50661- 20001.00	US United States	LEUKOCYTE EXPRESSION PROFILING	10/006,290 10/22/2001		60/241,994 10/20/2000 United States	National	WOHLGEMUTH, J. FRY, K. MATCUK, G. ALTMAN, P. PRENTICE, J. PHILLIPS, J. LY, N. WOODWARD, R. QUERTERMOUS, T. JOHNSON, F. XDX, INC. TO XDX INC. DBA	Expression Diagnostics, Inc.	Inactive Abandoned	

ATTY REF # CL/REF #	COUNTRY	TITLE	APP # FILE DATE	PATENT # GRANT DATE	PARENT # FILE DATE	FILE TYPE	INVENTOR(S)	OWNER	STATUS SUBSTATUS NEXT TAX	PENDING ACTIONS ACTION DUE DATE
50661- 20001.03	US United States	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTO IMMUNE AND CHRONIC INFLAMMATORY DISEASES	10/512,028 4/24/2003		PCT/US03/ 13015 4/24/2003 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC XDX, INC. TO XDX, INC. DBA EXPRESSION DIAG. TO XDX, INC.	XDx, Inc.	Filed	Issue FEE DUE-FINAL 8/26/2009 Reconsider Term Ext 8/26/2009 File Con/Div Appln? 8/26/2009
50661- 20001.04	US United States	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION	10/511,937 4/24/2003		PCT/US03/ 12946 4/24/2003 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC PRENTICE, JAMES MORRIS, MACDONALD ROSENBERG, STEVEN PRENTICE, JAMES EXPRESSION DIAG. TO XDX, INC.	XDx, Inc.	Filed	FRej Resp Due 9/18/2009 Ntc Appeal Due 9/18/2009

ATTY REF # CLIF REF #	COUNTRY	TITLE	APP # FILE DATE	PATENT # GRANT DATE	PARENT # FILE DATE	FILE TYPE	INVENTOR(S)	OWNER	STATUS SUBSTATUS NEXT TAX	PENDING ACTIONS ACTION DUE DATE
50661- 20001.06	US United States	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION	12/544,182 8/19/2009	7,579,148 08/25/2009 Expiry: 04/24/2022	10/511,937 4/24/2003 United States	National	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC PRENTICE, JAMES MORRIS, MACDONALD ROSENBERG, STEVEN PRENTICE, JAMES	XDx, Inc.	Filed	Assignment Due 9/19/2009 Power Atty Due 9/19/2009 Redacted Publication Deadline 10/19/2009
50661- 20001.10	US United States	METHODS AND COMPOSITIONS FOR DIAGNOSING OR MONITORING AUTOIMMUNE AND CHRONIC INFLAMMATORY DISEASES	10/990,298 11/15/2004	7,579,148 08/25/2009 Expiry: 04/24/2022	10/131,827 4/24/2002 United States	National	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC EXPRESSION DIAG. TO XDX, INC.	XDx, Inc.	Granted Client Pays MF/Ann 2/25/2013	Reissue Appln 8/25/2011 1st Maint Fee Due 2/25/2013 2nd Maint Fee Due 2/25/2017 3rd Maint Fee Due 2/25/2021
50661- 20001.11	US United States	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION	10/990,275 11/15/2004		10/131,831 4/24/2002 United States	National	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC EXPRESSION DIAG. TO XDX, INC.	XDx, Inc.	Filed	Confirm Abandonment 9/4/2009
50661- 20001.12	US United States	METHODS AND COMPOSITIONS FOR DIAGNOSING OR MONITORING AUTOIMMUNE AND CHRONIC INFLAMMATORY DISEASES	12/235,969 9/23/2008		10/990,298 11/15/2004 United States	National	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC	XDx, Inc.	Filed	

ATTY REF # CLIREF #	COUNTRY	TITLE	APP # FILE DATE	PATENT # GRANT DATE	PARENT # FILE DATE	FILE TYPE	INVENTOR(S)	OWNER	STATUS SUBSTATUS NEXT TAX	PENDING ACTIONS ACTION DUE DATE
50661- 20001.13	US United States	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION	12/329,173 12/5/2008		10/990,275 11/15/2004 United States	National	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC	XDx, Inc.	Filed	Redacted Publication Deadline 9/5/2009
50661- 20001.14	US United States	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTO IMMUNE AND CHRONIC INFLAMMATORY DISEASES			10/512,028 4/24/2003 United States	National	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC	XDx, Inc.	Docketed	
50661- 20001.20	US United States	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTOIMMUNE AND CHRONIC INFLAMMATORY DISEASES	10/131,827 4/24/2002	6,905,827 06/14/2005 Expiry: 10/22/2021	10/006,290 10/22/2001 United States	National	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC EXPRESSION DIAG. TO XDX, INC.	XDx, Inc.	Granted Client Pays MF/Ann 12/14/2012	
50661- 20001.21	US United States	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION	10/131,831 4/24/2002	7,026,121 04/11/2006 Expiry: 10/22/2021	10/006,290 10/22/2001 United States	National	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC EXPRESSION DIAG. TO XDX, INC.	XDx, Inc.	Granted Client Pays MF/Ann 10/11/2009	

ATTY REF # CLIENT #	COUNTRY	TITLE	APP # FILE DATE	PATENT # GRANT DATE	PARENT # FILE DATE	FILE TYPE	INVENTOR(S)	OWNER	STATUS SUBSTATUS NEXT TAX	PENDING ACTIONS ACTION DUE DATE
50661- 20001.22	US United States	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION	10/325,899 12/20/2002	7,235,358 06/26/2007 Expiry: 04/24/2022	10/131,831 4/24/2002 United States	National	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC PRENTICE, JAMES XDX, INC. TO XDX, INC. DBA EXPRESSION DIAG. TO XDX, INC.	XDX, Inc.	Granted Client Pays MF/Ann 12/26/2010	
50661- 20001.23	US United States	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION			10/511,937 4/24/2003 United States	National	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC PRENTICE, JAMES MORRIS, MACDONALD ROSENBERG, STEVEN PRENTICE, JAMES			In preparation
50661- 20001.40	WO Patent Cooperation Treaty	LEUKOCYTE EXPRESSION PROFILING	PCT/US01/ 47856 10/22/2001		60/241,994 10/20/2000 United States	Patent Cooperatio n Treaty	WOHLGEMUTH, J. FRY, K. MATCUK, G. ALTMAN, P. PRENTICE, J. PHILLIPS, J. LY, N. WOODWARD, R. QUERTERMOUS, T. JOHNSON, F.	Expression Diagnostics, Inc.	Inactive Converted	

<u>ATTY REF # CLARE #</u>	<u>COUNTRY</u>	<u>TITLE</u>	<u>APP # FILE DATE</u>	<u>PATENT # GRANT DATE</u>	<u>PARENT # FILE DATE</u>	<u>FILE TYPE</u>	<u>INVENTOR(S)</u>	<u>OWNER</u>	<u>STATUS SUBSTATUS NEXT TAX</u>	<u>PENDING ACTIONS ACTION DUE DATE</u>
50661- 20001.41	AU Australia	LEUKOCYTE EXPRESSION PROFILING	200224817 6 10/22/2001		PCT/US01/ 47856 10/22/2001 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	WOHLGEMUTH, J. FRY, K. MATCUK, G. ALTMAN, P. PRENTICE, J. PHILLIPS, J. LY, N. WOODWARD, R. QUERTERMOUS, T. JOHNSON, F.	Expression Diagnostics, Inc.	Inactive Abandoned	
50661- 20001.42	CA Canada	LEUKOCYTE EXPRESSION PROFILING	2426540 10/22/2001		PCT/US01/ 47856 10/22/2001 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	WOHLGEMUTH, J. FRY, K. MATCUK, G. ALTMAN, P. PRENTICE, J. PHILLIPS, J. LY, N. WOODWARD, R. QUERTERMOUS, T. JOHNSON, F.	Expression Diagnostics, Inc.	Filed Client Pays MF/Ann 10/22/2009	
50661- 20001.43	EP European Patent Convention	LEUKOCYTE EXPRESSION PROFILING	019970557 10/22/2001		PCT/US01/ 47856 10/22/2001 Patent Cooperatio n Treaty	PCT/EPC Application	WOHLGEMUTH, J. FRY, K. MATCUK, G. ALTMAN, P. PRENTICE, J. PHILLIPS, J. LY, N. WOODWARD, R. QUERTERMOUS, T. JOHNSON, F.	Expression Diagnostics, Inc.	Filed Client Pays MF/Ann 10/31/2009	

ATTY REF # CLIREF #	COUNTRY	TITLE	APP # FILE DATE	PATENT # GRANT DATE	PARENT # FILE DATE	FILE TYPE	INVENTOR(S)	OWNER	STATUS SUBSTATUS NEXT TAX	PENDING ACTIONS ACTION DUE DATE
50661- 20001.44	IL Israel	LEUKOCYTE EXPRESSION PROFILING	155430 10/22/2001		PCT/US01/ 47856 10/22/2001 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	WOHLGEMUTH, J. FRY, K. MATCUK, G. ALTMAN, P. PRENTICE, J. PHILLIPS, J. LY, N. WOODWARD, R. QUERTERMOUS, T. JOHNSON, F.	Expression Diagnostics, Inc.	Inactive Client Pays MF/Ann	
50661- 20001.45	IN India	LEUKOCYTE EXPRESSION PROFILING	470AKOL NP2003 10/22/2001		PCT/US01/ 47856 10/22/2001 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	WOHLGEMUTH, J. FRY, K. MATCUK, G. ALTMAN, P. PRENTICE, J. PHILLIPS, J. LY, N. WOODWARD, R. QUERTERMOUS, T. JOHNSON, F.	Expression Diagnostics, Inc.	Inactive Client Pays MF/Ann	
50661- 20001.46	NZ New Zealand	LEUKOCYTE EXPRESSION PROFILING	525336 10/22/2001	525336 07/13/2006 Expiry: 10/22/2021	PCT/US01/ 47856 10/22/2001 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	WOHLGEMUTH, J. FRY, K. MATCUK, G. ALTMAN, P. PRENTICE, J. PHILLIPS, J. LY, N. WOODWARD, R. QUERTERMOUS, T. JOHNSON, F.	Expression Diagnostics, Inc.	Inactive Client Pays MF/Ann	

ATTY REF # CLI REF #	COUNTRY	TITLE	APP # FILE DATE	PATENT # GRANT DATE	PARENT # FILE DATE	FILE TYPE	INVENTOR(S)	OWNER	STATUS SUBSTATUS NEXT TAX	PENDING ACTIONS ACTION DUE DATE
50661- 20001.47	SG Singapore	LEUKOCYTE EXPRESSION PROFILING	200302150 8 10/22/2001	98514 07/29/2005 Expiry: 10/22/2021	PCT/US01/ 47856 10/22/2001 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	WOHLGEMUTH, J. FRY, K. MATCUK, G. ALTMAN, P. PRENTICE, J. PHILLIPS, J. LY, N. WOODWARD, R. QUERTERMOUS, T. JOHNSON, F.	Expression Diagnostics, Inc.	Inactive Client Pays MF/Ann	
50661- 20001.48	ZA South Africa	LEUKOCYTE EXPRESSION PROFILING	20033132 10/22/2001	20033132 11/24/2004 Expiry: 10/22/2021	PCT/US01/ 47856 10/22/2001 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	WOHLGEMUTH, J. FRY, K. MATCUK, G. ALTMAN, P. PRENTICE, J. PHILLIPS, J. LY, N. WOODWARD, R. QUERTERMOUS, T. JOHNSON, F.	Expression Diagnostics, Inc.	Granted Client Pays MF/Ann 10/22/2009	
50661- 20001.49	WO Patent Cooperation Treaty	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTO IMMUNE AND CHRONIC INFLAMMATORY DISEASES	PCT/US03/ 13015 4/24/2003		10/131,827 4/24/2002 United States	Patent Cooperatio n Treaty	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC	Expression Diagnostics, Inc.	Inactive Dropped	

ATTY REF # CLIREF #	COUNTRY	TITLE	APP # FILE DATE	PATENT # GRANT DATE	PARENT # FILE DATE	FILE TYPE	INVENTOR(S)	OWNER	STATUS SUBSTATUS NEXT TAX	PENDING ACTIONS ACTION DUE DATE
50661- 20001.50	WO Patent Cooperation Treaty	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AND TRANSPLANT REJECTION	PCT/US03/ 12946 4/24/2003		10/325,899 12/20/2002 United States	Patent Cooperatio n Treaty	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC PRENTICE, JAMES MORRIS, MACDONALD ROSENBERG, STEVEN PRENTICE, JAMES	Expression Diagnostics, Inc.	Inactive Converted	
50661- 20001.51	JP Japan	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTO IMMUNE AND CHRONIC INFLAMMATORY DISEASES	200358733 3 4/24/2003		PCT/US03/ 13015 4/24/2003 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC	XDx, Inc.	Filed Client Pays MF/Ann	1-OA RESP DUE-FINAL 9/26/2009
50661- 20001.52	AU Australia	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AND TRANSPLANT REJECTION	200329946 5 4/24/2003	200329946 5 05/31/2007 Expiry: 04/24/2023	PCT/US03/ 12946 4/24/2003 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC PRENTICE, JAMES MORRIS, MACDONALD ROSENBERG, STEVEN PRENTICE, JAMES	Expression Diagnostics, Inc.	Granted Client Pays MF/Ann 4/24/2010	
50661- 20001.53	CA Canada	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AND TRANSPLANT REJECTION	2483481 4/24/2003		PCT/US03/ 12946 4/24/2003 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC PRENTICE, JAMES MORRIS, MACDONALD ROSENBERG, STEVEN PRENTICE, JAMES	Expression Diagnostics, Inc.	Filed Client Pays MF/Ann 4/24/2010	

ATTY REF # CLIREF #	COUNTRY	TITLE	APP # FILE DATE	PATENT # GRANT DATE	PARENT # FILE DATE	FILE TYPE	INVENTOR(S)	OWNER	STATUS SUBSTATUS NEXT TAX	PENDING ACTIONS ACTION DUE DATE
50661- 20001.54	EP European Patent Convention	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION	037997558 4/24/2003		PCT/US03/ 12946 4/24/2003 Patent Cooperatio n Treaty	PCT/EPC Application	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC PRENTICE, JAMES MORRIS, MACDONALD ROSENBERG, STEVEN PRENTICE, JAMES	Expression Diagnostics, Inc.	Filed Client Pays MF/Ann 4/30/2010	
50661- 20001.55	IN India	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION	1741KOLN P2004 4/24/2003	221136 06/18/2008 Expiry: 04/24/2023	PCT/US03/ 12946 4/24/2003 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC PRENTICE, JAMES MORRIS, MACDONALD ROSENBERG, STEVEN PRENTICE, JAMES	Expression Diagnostics, Inc.	Inactive Client Pays MF/Ann	
50661- 20001.56	IL Israel	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION	164804 4/24/2003		PCT/US03/ 12946 4/24/2003 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC PRENTICE, JAMES MORRIS, MACDONALD ROSENBERG, STEVEN PRENTICE, JAMES	Expression Diagnostics, Inc.	Inactive Abandoned	
50661- 20001.57	NZ New Zealand	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION	536751 4/24/2003		PCT/US03/ 12946 4/24/2003 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC PRENTICE, JAMES MORRIS, MACDONALD ROSENBERG, STEVEN PRENTICE, JAMES	Expression Diagnostics, Inc.	Inactive Abandoned	

ATTY REF # CLI REF #	COUNTRY	TITLE	APP # FILE DATE	PATENT # GRANT DATE	PARENT # FILE DATE	FILE TYPE	INVENTOR(S)	OWNER	STATUS SUBSTATUS NEXT TAX	PENDING ACTIONS ACTION DUE DATE
50661- 20001.58	SG Singapore	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION	200406287 3 4/24/2003	109052 06/30/2008 Expiry: 04/24/2023	PCT/US03/ 12946 4/24/2003 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC PRENTICE, JAMES MORRIS, MACDONALD ROSENBERG, STEVEN PRENTICE, JAMES	Expression Diagnostics, Inc.	Inactive Client Pays MF/Ann	
50661- 20001.59	ZA South Africa	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION	20049420 4/24/2003	20049420 05/30/2007 Expiry: 04/24/2023	PCT/US03/ 12946 4/24/2003 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC PRENTICE, JAMES MORRIS, MACDONALD ROSENBERG, STEVEN PRENTICE, JAMES	Expression Diagnostics, Inc.	Granted Client Pays MF/Ann 4/24/2010	
50661- 20001.60	JP Japan	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION	200454987 4 4/24/2003		PCT/US03/ 12946 4/24/2003 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC PRENTICE, JAMES MORRIS, MACDONALD ROSENBERG, STEVEN PRENTICE, JAMES	XDx, Inc.	Filed Client Pays MF/Ann	1-OA RESP DUE-FINAL 9/27/2009
50661- 20001.61	EP European Patent Convention	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION	080169709 9/26/2008		037997558 4/24/2003 European Patent Convention	European Patent Case	WOHLGEMUTH, JAY FRY, KIRK WOODWARD, ROBERT LY, NGOC PRENTICE, JAMES MORRIS, MACDONALD ROSENBERG, STEVEN PRENTICE, JAMES	XDx, Inc.	Filed Client Pays MF/Ann 4/30/2010	

ATTY REF # CLL REF #	COUNTRY	TITLE	APP # FILE DATE	PATENT # GRANT DATE	PARENT # FILE DATE	FILE TYPE	INVENTOR(S)	OWNER	STATUS SUBSTATUS NEXT TAX	PENDING ACTIONS ACTION DUE DATE
50661- 20005.00	US United States	CARDIAC TRANSPLANT REJECTION				National	WOHLGEMUTH, JAY	Biocardia, Inc.	Inactive Closed	
50661- 20006.00	US United States	DETECTION OF LUPUS				National	WOHLGEMUTH, JAY	Biocardia, Inc.	Inactive Closed	
50661- 20010.00	US United States	METHODS OF MONITORING FUNCTIONAL STATUS OF TRANSPLANTS USING GENE PANELS	11/433,191 5/11/2006		60/680,442 5/11/2005 United States	National	ROSENBERG, STEVE LAL, PREETI FRY, KIRK E. KLINGLER, TOD M. WALTHER, DIRK WOODWARD, ROBERT N. EXPRESSION DIAG. TO XDX, INC.	XDX, Inc.	Filed	
50661- 20010.40	WO Patent Cooperation Treaty	METHODS OF MONITORING FUNCTIONAL STATUS OF TRANSPLANTS USING GENE PANELS	PCT/US200 6/18381 5/11/2006		60/680,442 5/11/2005 United States	Patent Cooperatio n Treaty	ROSENBERG, STEVE LAL, PREETI FRY, KIRK E. KLINGLER, TOD M. WALTHER, DIRK WOODWARD, ROBERT N.		Inactive Converted	
50661- 20010.41	EP European Patent Convention	METHODS OF MONITORING FUNCTIONAL STATUS OF TRANSPLANTS USING GENE PANELS	067702555 5/11/2006		PCT/US200 6/18381 5/11/2006 Patent Cooperatio n Treaty	PCT/EPC Application	ROSENBERG, STEVE LAL, PREETI FRY, KIRK E. KLINGLER, TOD M. WALTHER, DIRK WOODWARD, ROBERT N.		Filed 5/31/2010	

ATTY REF # CLIF REF #	COUNTRY	TITLE	APP # FILE DATE	PATENT # GRANT DATE	PARENT # FILE DATE	FILE TYPE	INVENTOR(S)	OWNER	STATUS SUBSTATUS NEXT TAX	PENDING ACTIONS ACTION DUE DATE
50661- 20011.00	US United States	FOUR NOVEL GENES USEFUL FOR DIAGNOSING AND MONITORING INFLAMMATION RELATED DISORDERS	11/223,492 9/8/2005		60/608,403 9/8/2004 United States	National	WOHLGEMUTH, JAY LAL, PREETI TAYAMA, DARREN WALTHER, DIRK EXPRESSION DIAG. TO XDX, INC.	XDx, Inc.	Filed	Issue Fee Due-1 M Remnd 10/21/2009 File Con/Div Appln? 11/21/2009 Issue FEE DUE-FINAL 11/21/2009
50661- 20011.40	WO Patent Cooperation Treaty	GENES USEFUL FOR DIAGNOSING AND MONITORING INFLAMMATION RELATED DISORDERS	PCT/US200 5/31806 9/8/2005		60/608,403 9/8/2004 United States	Patent Cooperatio n Treaty	WOHLGEMUTH, JAY TAYAMA, DARREN WALTHER, DIRK LAL, PREETI		Inactive Abandoned	
50661- 20015.00	US United States	STEROID RESPONSIVE NUCLEIC ACID EXPRESSION AND PREDICTION OF DISEASE ACTIVITY	11/784,998 4/9/2007		60/790,474 4/7/2006 United States	National	LAL, PREETI ROSENBERG, STEVEN KLINGER, TOD EXPRESSION DIAG. TO XDX, INC.	XDx, Inc.	Filed	1-OA Resp Due 8/29/2009
50661- 20015.40	WO Patent Cooperation Treaty	STEROID RESPONSIVE GENES	PCT/US200 7/08909 4/9/2007		60/790,474 4/7/2006 United States	Patent Cooperatio n Treaty	ROSENBERG, STEVEN		Inactive Closed	
50661- 20015.41	AU Australia	STEROID RESPONSIVE GENES	200730972 6 4/9/2007		PCT/US200 7/08909 4/9/2007 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	ROSENBERG, STEVEN	XDx, Inc.	Inactive	
50661- 20015.42	CA Canada	STEROID RESPONSIVE GENES	2648380 4/9/2007		PCT/US200 7/08909 4/9/2007 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	ROSENBERG, STEVEN	XDx, Inc.	Filed 4/9/2010	Annuity Due 4/9/2010 Req Exam Due 4/9/2012

ATTY REF # CLIR REF #	COUNTRY	TITLE	APP # FILE DATE	PATENT # GRANT DATE	PARENT # FILE DATE	FILE TYPE	INVENTOR(S)	OWNER	STATUS SUBSTATUS NEXT TAX	PENDING ACTIONS ACTION DUE DATE
50661- 20015.43	EP European Patent Convention	STEROID RESPONSIVE GENES	078612835 4/9/2007		PCT/US200 7/08909 4/9/2007 Patent Cooperatio n Treaty	PCT/EPC Application	ROSENBERG, STEVEN	XDx, Inc.	Filed 4/30/2010	
50661- 20015.44	IL Israel	STEROID RESPONSIVE GENES	194646 4/9/2007		PCT/US200 7/08909 4/9/2007 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	ROSENBERG, STEVEN	XDx, Inc.	Inactive	
50661- 20015.45	IN India	STEROID RESPONSIVE GENES	4491KOLN P2008 4/9/2007		PCT/US200 7/08909 4/9/2007 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	ROSENBERG, STEVEN	XDx, Inc.	Inactive	
50661- 20015.46	NZ New Zealand	STEROID RESPONSIVE NUCLEIC ACID EXPRESSION AND PREDICTION OF DISEASE ACTIVITY	572641 4/9/2007		PCT/US200 7/08909 4/9/2007 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	ROSENBERG, STEVEN	XDx, Inc.	Inactive	
50661- 20015.47	SG Singapore	STEROID RESPONSIVE GENES	200807420 5 4/9/2007		PCT/US200 7/08909 4/9/2007 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	ROSENBERG, STEVEN	XDx, Inc.	Inactive	

ATTY REF # CL/REF #	COUNTRY	TITLE	APP # FILE DATE	PATENT # GRANT DATE	PARENT # FILE DATE	FILE TYPE	INVENTOR(S)	OWNER	STATUS SUBSTATUS NEXT TAX	PENDING ACTIONS ACTION DUE DATE
50661- 20016.00	US United States	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING THE STATUS OF TRANSPLANT REJECTION AND IMMUNE DISORDERS	11/893,236 8/14/2007		60/837,698 8/14/2006 United States	National	ROSENBERG, STEVEN FRY, KIRK WU, BIN DEDRICK, RUSSELL L. EXPRESSION DIAG. TO XDX, INC.	XDx, Inc.	Filed	1-OA Resp Due 8/29/2009
50661- 20016.40	WO Patent Cooperation Treaty	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING THE STATUS OF TRANSPLANT REJECTION AND IMMUNE DISORDERS	PCT/US200 7/18135 8/14/2007		60/837,698 8/14/2006 United States	Patent Cooperatio n Treaty	ROSENBERG, STEVEN FRY, KIRK WU, BIN DEDRICK, RUSSELL L.		Inactive	
50661- 20016.41	EP European Patent Convention	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING THE STATUS OF TRANSPLANT REJECTION AND IMMUNE DISORDERS			PCT/US200 7/18135 8/14/2007 Patent Cooperatio n Treaty	PCT/EPC Application	ROSENBERG, STEVEN FRY, KIRK WU, BIN DEDRICK, RUSSELL L.		Inactive Closed	
50661- 20017.00	US United States	METHODS FOR DIAGNOSING AND MONITORING THE STATUS OF SYSTEMIC LUPUS ERYTHEMATOSUS	11/938,227 11/9/2007		60/858,147 11/9/2006 United States	National	LAL, PREETI G. WILLIAMS, GAVIN E. FRY, KIRK E. SUN, JINGTAO DEDRICK, RUSSELL	XDx, Inc.	Filed	Assign Due- Extended 9/9/2009

ATTY REF # CL/REF #	COUNTRY	TITLE	APP # FILE DATE	PATENT # GRANT DATE	PARENT # FILE DATE	FILE TYPE	INVENTOR(S)	OWNER	STATUS SUBSTATUS NEXT TAX	PENDING ACTIONS ACTION DUE DATE
50661- 20017.40	WO Patent Cooperation Treaty	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING THE STATUS OF SYSTEMATIC LUPUS ERYTHEMATOSUS	PCT/US200 7/23675 11/9/2007		60/858,147 11/9/2006 United States	Patent Cooperatio n Treaty	LAL, PREETI G. WILLIAMS, GAVIN E. FRY, KIRK E. SUN, JINGTAO DEDRICK, RUSSELL		Inactive Converted	
50661- 20017.41	EP European Patent Convention	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING THE STATUS OF SYSTEMATIC LUPUS ERYTHEMATOSUS	078741238 11/9/2007		PCT/US200 7/23675 11/9/2007 Patent Cooperatio n Treaty	PCT/EPC Application	LAL, PREETI G. WILLIAMS, GAVIN E. FRY, KIRK E. SUN, JINGTAO DEDRICK, RUSSELL	XDx, Inc.	Filed 11/30/2009	
50661- 20017.42	JP Japan	METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING THE STATUS OF SYSTEMATIC LUPUS ERYTHEMATOSUS			PCT/US200 7/23675 11/9/2007 Patent Cooperatio n Treaty	Patent Cooperatio n Treaty	LAL, PREETI G. WILLIAMS, GAVIN E. FRY, KIRK E. SUN, JINGTAO DEDRICK, RUSSELL		Inactive Closed	
50661- 20019.00	US United States	GHOST FILE -- IDENTIFICATION, MONITORING AND TREATMENT OF DISEASE AND CHARACTERIZATIO N OF BIOLOGICAL CONDITION USING GENE EXPRESSION PROFILES				National			Inactive Ghost File	

<u>ATTY REF #</u> <u>CLIF REF #</u>	<u>COUNTRY</u>	<u>TITLE</u>	<u>APP #</u> <u>FILE</u> <u>DATE</u>	<u>PATENT #</u> <u>GRANT</u> <u>DATE</u>	<u>PARENT #</u> <u>FILE</u> <u>DATE</u>	<u>FILE</u> <u>TYPE</u>	<u>INVENTOR(S)</u>	<u>OWNER</u>	<u>STATUS</u> <u>SUBSTATUS</u> <u>NEXT TAX</u>	<u>PENDING</u> <u>ACTIONS</u> <u>ACTION DUE DATE</u>
50661- 20019.30	US United States	IDENTIFICATION, MONITORING AND TREATMENT OF DISEASE AND CHARACTERIZATIO N OF BIOLOGICAL CONDITION USING GENE EXPRESSION PROFILES (REEXAMINATION OF USP 6,964,850)	95/001,032 3/17/2008			National	BEVILACQUA, MICHAEL P.		Filed Re- examination	Resp Due 9/5/2009

SCHEDULE B
TRADEMARKS

Status Report for XDX, Inc.
 Client Number: 50661
 August 26, 2009

<u>MoFo Matter Number</u>	<u>Mark Serial Number Registration Number Applicant</u>	<u>Country</u>	<u>Class/Goods and Services</u>	<u>Status</u>
50661-24001.00	ALLOMAP Serial No: 78/353,208 Reg. No: 3,442,169 XDX, Inc.	United States	Class: 5 Biological chemical test kits for medical laboratory use in analysis of gene expression in inflammatory and cardiovascular diseases and disorders	Registered App Date: 1/16/2004 Reg Date: 6/3/2008 8&15 Due Date: 6/3/2014
50661-24001.01	ALLOMAP Serial No: 78/516,396 Reg. No: 3,143,352 XDX, Inc.	United States	Class: 44 Medical diagnostic services, namely gene expression testing to determine immune response	Registered App Date: 11/12/2004 Reg Date: 9/12/2006 8&15 Due Date: 9/12/2012
50661-24001.40	ALLOMAP Serial No: 1010448 Reg. No: 1010448 Expression Diagnostics, Inc.	Australia	Class: 5 Biological chemical diagnostic test kits for clinical or medical laboratory use, namely, for use in analysis of gene expression, genetics, single nucleotide polymorphism, haplotypes, proteins, and biological samples, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug responses; diagnostic medical reagents, chemicals and solid matrix materials for biological clinical or medical laboratory use for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases, developmental disorders and cancer. Priority claimed: Biological chemical diagnostic test kits for clinical or medical laboratory use, namely, for use in analysis of gene expression, genetics, single nucleotide polymorphism, haplotypes, proteins, and biological samples, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug responses, diagnostic medical reagents, chemicals and solid matrix materials for biological, clinical or medical laboratory use for use in diagnosing inflammatory, infectious central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases, developmental disorders and cancer	Registered App Date: 7/9/2004 Reg Date: 7/9/2004 Renewal Date: 7/9/2014
50661-24001.42	ALLOMAP	Canada	Goods:	Filed

* Change of name to XDX, Inc. has not been recorded in this country yet. Awaiting client's instructions to proceed with recordal.

50661-24001.43	<p>Serial No: 1223029 Reg. No: Expression Diagnostics, Inc. *</p>	Europe *	<p>Biological chemical diagnostic test kits for clinical or medical laboratory use, namely, for use in analysis of gene expression, genetics, single nucleotide polymorphism, haplotypes, proteins, and biological samples, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug responses; diagnostic medical reagents, chemicals and solid matrix materials for biological clinical or medical laboratory use for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases, developmental disorders and cancer</p>	<p>App Date: 7/9/2004 Allowed 3/11/2005 Use Declaration/Reg Fees Due: 1/8/2010</p>
50661-24001.44	<p>ALLOMAP Serial No: 2004063423 Reg. No: 4917709 Expression Diagnostics, Inc. *</p>	Japan	<p>Class: 5 Reagent kits for diagnostic tests consisting of chemicals, machines, parts and the like for biological clinical or medical laboratory purpose for use in analysis of gene expression, genetics, single nucleotide polymorphism, haplotypes, proteins, and biological samples, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug responses; diagnostic medical reagents for biological clinical or medical laboratory purpose for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases, developmental disorders and cancer; pharmaceutical, veterinary and sanitary preparations; semen for artificial insemination</p>	<p>Registered App Date: 7/8/2004 Reg Date: 12/22/2005 Renewal Date: 12/22/2015</p>

* Change of name to XDX, Inc. has not been recorded in this country yet. Awaiting client's instructions to proceed with recordal.
 * European Community Trademark Countries: Austria, Benelux (Belgium, The Netherlands and Luxembourg), Bulgaria, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Portugal, Romania, Spain, Sweden, United Kingdom, Cyprus, The Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Slovakia, and Slovenia.
 * Change of name to XDX, Inc. has not been recorded in this country yet. Awaiting client's instructions to proceed with recordal.

50661-24001.45	ALLOMAP Serial No: 200412797 Reg. No: 229407 Expression Diagnostics, Inc.	Norway	Class: 5 Biological chemical diagnostic test kits for clinical or medical laboratory use, namely, for use in analysis of gene expression, genetics, single nucleotide polymorphism, haplotypes, proteins, and biological samples, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug responses; diagnostic medical reagents, chemicals and solid matrix materials for biological clinical or medical laboratory use for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases, developmental disorders and cancer Class: 42 Diagnostic services, namely gene expression testing to determine immune response	Registered App Date: 12/13/2004 Reg Date: 11/19/2005 Proof of Use Due: 11/19/2010 Renewal Date: 11/19/2015
50661-24001.46	ALLOMAP Serial No: 507902005 Reg. No: 537106 Expression Diagnostics, Inc.	Switzerland	Class: 5 Biological chemical diagnostic test kits consisting of preparations for clinical or medical laboratory use, namely, for use in analysis of gene expression, genetics, single nucleotide polymorphism, haplotypes, proteins, and biological samples, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug responses; diagnostic medical reagents, chemicals and solid matrix materials for biological clinical or medical laboratory use for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases, developmental disorders and cancer Class: 42 Chemical analysis of gene expression to determine immune response Class: 44 Diagnostic services, namely gene expression testing to determine immune response	Registered App Date: 2/1/2005 Reg Date: 9/13/2005 Renewal Date: 2/1/2015
50661-24001.47	ALLOMAP Serial No: 1053815 Reg. No: 1053815 Expression Diagnostics, Inc.	Australia	Class: 42 Diagnostic services, namely gene expression testing to determine immune response	Registered App Date: 5/5/2005 Reg Date: 9/5/2005 Proof of Use Due: 5/5/2010 Renewal Date: 5/5/2015
50661-24001.49	ALLOMAP Serial No: 1256701 Reg. No: Expression Diagnostics, Inc.	Canada	Services: Diagnostic services, namely gene expression testing to determine immune response	Filed App Date: 5/5/2005 Allowed 1/27/2006 Use Declaration/Reg Fees Due: 11/4/2009

* Change of name to XDX, Inc. has not been recorded in this country yet. Awaiting client's instructions to proceed with recordal.

sf-2732180

50661-24001.50	ALLOMAP Serial No: 004439287 Reg. No: 004439287	Europe*	Class: 42 Diagnostic services, namely gene expression testing to determine immune response	Registered App Date: 5/10/2005 Reg Date: 6/30/2006 Renewal Date: 5/31/2015
50661-24001.51	XDX, Inc. ALLOMAP Serial No: 200540188 Reg. No: 4952272	Japan	Class: 44 Gene expression testing to determine immune response for the purpose of medical diagnostic or treatment	Registered App Date: 5/9/2005 Reg Date: 5/12/2006 Renewal Date: 5/12/2016
50661-24002.40	EXPRESSION DIAGNOSTICS Serial No: 1006539 Reg. No: 1006539	Australia	Class: 5 Biological chemical diagnostic test kits for clinical or medical laboratory use, namely, for use in analysis of gene expression, genetics, single nucleotide polymorphism, haplotypes, proteins, and biological samples, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug responses; diagnostic medical reagents, chemicals and solid matrix materials for biological, clinical or medical laboratory use for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases, developmental disorders and cancer	Registered App Date: 6/15/2004 Reg Date: 6/15/2004 Renewal Date: 6/15/2014
50661-24002.43	EXPRESSION DIAGNOSTICS Serial No: 003887866 Reg. No: 003887866	Europe*	Class: 5 Biological chemical diagnostic test kits for clinical or medical laboratory use, namely, for use in analysis of gene expression, genetics, single nucleotide polymorphism, haplotypes, proteins, and biological samples, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug responses; diagnostic medical reagents, chemicals and solid matrix materials for biological, clinical or medical laboratory use for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases, developmental disorders and cancer	Registered App Date: 6/16/2004 Reg Date: 10/19/2005 Renewal Date: 6/16/2014
50661-24002.45	EXPRESSION DIAGNOSTICS Serial No: 200412788 Reg. No: 229405	Norway	Class: 5 Biological chemical diagnostic test kits for clinical or medical laboratory use, namely, for use in analysis of gene expression, genetics, single nucleotide polymorphism, haplotypes, proteins, and biological samples, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug responses; diagnostic medical reagents, chemicals and solid matrix	Registered App Date: 12/13/2004 Reg Date: 11/19/2005 Proof of Use Due: 11/19/2010


* European Community Trademark Countries: Austria, Benelux (Belgium, The Netherlands & Luxembourg), Bulgaria, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Portugal, Romania, Spain, Sweden, United Kingdom, Cyprus, The Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Slovakia, and Slovenia.

* Change of name to XDX, Inc. has not been recorded in this country yet. Awaiting client's instructions to proceed with recordal.




sf-2732180

50661-24003.47	Expression Diagnostics, Inc. IMMUNOMAP Serial No: 1053816 Reg. No: 1053816	Australia	<p>materials for biological clinical or medical laboratory use for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases, developmental disorders and cancer</p> <p>Class: 42 Diagnostic services, namely gene expression testing to determine immune response</p> <p>Class: 42 Diagnostic services, namely gene expression testing to determine immune response</p>	<p>Renewal Date: 11/19/2015</p> <p>Registered App Date: 5/5/2005 Reg Date: 5/5/2005</p> <p>Proof of Use Due: 5/5/2010 Renewal Date: 5/5/2015</p>
50661-24004.40	Expression Diagnostics, Inc. XDX (STYLIZED) Serial No: 826191290 Reg. No: 826191290 XDX Expression Diagnostics, Inc.	Brazil	<p>Class: 5 Biological chemical diagnostic test kits for clinical or medical laboratory use, namely, for use in analysis of gene expression, genetics, single nucleotide polymorphism, haplotypes, proteins, and biological samples, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug responses; diagnostic medical reagents, chemicals and solid matrix materials for biological clinical or medical laboratory use for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases, developmental disorders and cancer</p> <p>Goods: Biological chemical diagnostic test kits for clinical or medical laboratory use, namely, for use in analysis of gene expression, genetics, single nucleotide polymorphism, haplotypes, proteins, and biological samples, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug responses; diagnostic medical reagents, chemicals and solid matrix materials for biological clinical or medical laboratory use for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases, developmental disorders and cancer</p>	<p>Registered App Date: 1/9/2004 Reg Date: 8/14/2007</p> <p>Renewal Date: 8/14/2017</p>
50661-24004.41	XDX (STYLIZED) Serial No: 1204066 Reg. No: XDX Expression Diagnostics, Inc.	Canada	<p>Goods: Biological chemical diagnostic test kits for clinical or medical laboratory use, namely, for use in analysis of gene expression, genetics, single nucleotide polymorphism, haplotypes, proteins, and biological samples, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug responses; diagnostic medical reagents, chemicals and solid matrix materials for biological clinical or medical laboratory use for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases, developmental disorders and cancer</p>	<p>Filed App Date: 1/26/2004 Allowed 10/29/2004</p> <p>Use Declaration/Reg Fees Due: 1/25/2010</p>
50661-24004.42	XDX (STYLIZED) Serial No: 003608049 Reg. No: 003608049 XDX XDX, Inc.	Europe *	<p>Class: 5 Biological chemical diagnostic test kits for clinical or medical laboratory use, namely, for use in analysis of gene expression, genetics, single nucleotide polymorphism, haplotypes, proteins, and biological samples, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug responses; diagnostic medical reagents, chemicals and solid matrix materials for biological clinical or medical laboratory use for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases, developmental disorders and cancer</p>	<p>Registered App Date: 1/13/2004 Reg Date: 6/4/2008</p> <p>Renewal Date: 1/13/2014</p>



* Change of name to XDX, Inc. has not been recorded in this country yet. Awaiting client's instructions to proceed with recordal.
* Change of name to XDX, Inc. has not been recorded in this country yet. Awaiting client's instructions to proceed with recordal.

50661-24004.43	<p>XDx (STYLIZED) Serial No: 2004008081 Reg. No: 4850872</p> <p>XDx</p> <p>Expression Diagnostics, Inc. *</p>	Japan	<p>Class: 5 Reagent for diagnostic tests which is in kit form for biological clinical or medical laboratory use for use in analysis of gene expression, genetics, single nucleotide polymorphism, proteins, and biological samples, for use in analysis of haplotypes, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug response; diagnostic medical reagents for biological clinical or medical laboratory use for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases, developmental disorders and cancer; chemical preparations for biological clinical or medical laboratory use for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases, developmental disorders and cancer; pharmaceutical, veterinary and sanitary preparations; oiled paper for medical purposes; sanitary masks; pharmaceutical water; gauze for dressings; empty capsules for pharmaceuticals; eye patches; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; colloidion; breast-nursing pads; dental materials; semen for artificial insemination</p>	<p>Registered App Date: 1/30/2004 Reg Date: 3/25/2005</p> <p>Renewal Date: 3/25/2015</p>
50661-24004.44	<p>XDx (STYLIZED) Serial No: 200412772 Reg. No: 229402</p> <p>XDx</p> <p>Expression Diagnostics, Inc. *</p>	Norway	<p>Class: 5 Biological chemical diagnostic test kits for clinical or medical laboratory use, namely, for use in analysis of gene expression, genetics, single nucleotide polymorphism, haplotypes, proteins, and biological samples, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug response; diagnostic medical reagents, chemicals and solid matrix materials for biological clinical or medical laboratory use for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases, developmental disorders and cancer</p> <p>Class: 42 Diagnostic services, namely gene expression testing to determine immune response</p>	<p>Registered App Date: 12/13/2004 Reg Date: 11/19/2005</p> <p>Proof of Use Due: 11/19/2010 Renewal Date: 11/19/2015</p>
50661-24005.00	<p>XDx EXPRESSION DIAGNOSTICS AND DESIGN Serial No: 78/438,424 Reg. No:</p>  <p>XDx, Inc.</p>	United States	<p>Class: 5 Biological chemical test kits for medical laboratory use in analysis of gene expression, diagnostic medical reagents for use in diagnosing inflammatory diseases and disorders</p>	<p>Filed - Intent to Use App Date: 6/21/2004 Allowed 2/21/2006</p> <p>No Action - awaiting registration</p>



* European Community Trademark Countries: Austria, Benelux (Belgium, The Netherlands & Luxembourg), Bulgaria, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Portugal, Romania, Spain, Sweden, United Kingdom, Cyprus, The Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Slovakia, and Slovenia.
 * Change of name to XDx, Inc. has not been recorded in this country yet. Awaiting client's instructions to proceed with recordal.

<p>50661-24005.01</p> <p>XDX EXPRESSION DIAGNOSTICS & DESIGN Serial No: 78/516,400 Reg. No: 3,199,533</p>  <p>XDX, Inc.</p>	<p>United States</p>	<p>Class: 44 Medical diagnostic services, namely, gene expression testing to determine immune response</p>	<p>Registered App Date: 11/12/2004 Reg Date: 1/16/2007 8&15 Due Date: 1/16/2013</p>
<p>50661-24005.40</p> <p>XDX EXPRESSION DIAGNOSTIC AND DESIGN Serial No: 1035232 Reg. No: 1035232</p>  <p>Expression Diagnostics, Inc.</p>	<p>Australia</p>	<p>Class: 5 Biological chemical diagnostic test kits for clinical or medical laboratory use, namely, for use in analysis of gene expression, genetics, single nucleotide polymorphism, haplotypes, proteins, and biological samples, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug responses; diagnostic medical reagents, chemicals and solid matrix materials for biological clinical or medical laboratory use for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases; developmental disorders and cancer</p> <p>Class: 42 Diagnostic services, namely gene expression testing to determine immune response</p>	<p>Registered App Date: 12/20/2004 Reg Date: 12/20/2004 Renewal Date: 12/20/2014</p>
<p>50661-24005.42</p> <p>XDX EXPRESSION DIAGNOSTIC AND DESIGN Serial No: 1241348 Reg. No:</p>  <p>Expression Diagnostics, Inc.</p>	<p>Canada</p>	<p>Goods: Biological chemical diagnostic test kits for clinical or medical laboratory use, namely, for use in analysis of gene expression, genetics, single nucleotide polymorphism, haplotypes, proteins, and biological samples, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug responses; diagnostic medical reagents, chemicals and solid matrix materials for biological clinical or medical laboratory use for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases; developmental disorders and cancer</p> <p>Services: Diagnostic services, namely gene expression testing to determine immune response</p>	<p>Filed App Date: 12/20/2004 Allowed 7/28/2006 Use Declaration/Reg Fees Due: 12/19/2009</p>
<p>50661-24005.43</p> <p>XDX EXPRESSION DIAGNOSTIC AND DESIGN</p>	<p>Europe *</p>	<p>Class: 5 Biological chemical diagnostic test kits for clinical or medical laboratory use, namely, for use in</p>	<p>Registered App Date: 12/21/2004</p>

* Change of name to XDX, Inc. has not been recorded in this country yet. Awaiting client's instructions to proceed with recordal.
 * Change of name to XDX, Inc. has not been recorded in this country yet. Awaiting client's instructions to proceed with recordal.
 * European Community Trademark Countries: Austria, Benelux (Belgium, The Netherlands & Luxembourg), Bulgaria, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Portugal, Romania, Spain, Sweden, United Kingdom, Cyprus, The Czech Republic, Estonia, Latvia, Lithuania, Malta, Poland, Slovakia, and Slovenia

<p>50661-24005.44</p>	<p>Serial No: 004226643 Reg. No: 004226643</p>  <p>XDX, Inc.</p>	<p>Japan</p>	<p>analysis of gene expression, genetics, single nucleotide polymorphism, haplotypes, proteins, and biological samples, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug responses; diagnostic medical reagents, chemicals and solid matrix materials for biological clinical or medical laboratory use for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases; developmental disorders and cancer</p> <p>Class: 42 Diagnostic testing services; diagnostic services, namely gene expression testing to determine immune response</p>	<p>Reg Date: 5/17/2006 Renewal Date: 12/31/2014</p>
<p>50661-24005.44</p>	<p>XDX EXPRESSION DIAGNOSTIC AND DESIGN Serial No: 2004116009 Reg. No: 4968092</p>  <p>Expression Diagnostics, Inc.</p>	<p>Japan</p>	<p>Class: 5 Reagent kits for diagnostic tests consisting of chemicals, machines, parts and the like for biological clinical or medical laboratory purpose for use in analysis of gene expression, genetics, single nucleotide polymorphism, haplotypes, proteins, and biological samples, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug responses; diagnostic medical reagents for biological clinical or medical laboratory purpose for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases; developmental disorders and cancer; chemical preparations for biological clinical or medical laboratory purpose for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases; developmental disorders and cancer; pharmaceutical, veterinary and sanitary preparations; semen for artificial insemination</p> <p>Class: 42 Gene expression testing to determine immune response; and other gene testing, inspection, diagnosis or research; consultancy and providing information relating to gene testing, inspection, diagnosis or research; testing, inspection or research of pharmaceuticals, chemicals, cosmetics or foodstuff; consultancy and providing information relating to testing, inspection or research of pharmaceuticals, chemicals, cosmetics or foodstuff; computer software design, computer programming, or maintenance of computer software; testing, inspection or research on agriculture, livestock breeding or fisheries; testing or research on machines, apparatus and instruments; rental of computers; providing computer programs; rental of laboratory apparatus and instruments</p>	<p>Registered App Date: 12/20/2004 Reg Date: 7/7/2006 Renewal Date: 7/7/2016</p>

* Change of name to XDX, Inc. has not been recorded in this country yet. Awaiting client's instructions to proceed with recordal.

50661-24005.45	<p>XDX EXPRESSION DIAGNOSTICS AND DESIGN Serial No: 200412786 Reg. No: 229404</p>  <p>Expression Diagnostics, Inc. *</p>	Norway	<p>Class: 5 Biological chemical diagnostic test kits for clinical or medical laboratory use, namely, for use in analysis of gene expression, genetics, single nucleotide polymorphism, haplotypes, proteins, and biological samples, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug responses; diagnostic medical reagents, chemicals and solid matrix materials for biological clinical or medical laboratory use for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases, developmental disorders and cancer</p> <p>Class: 42 Diagnostic services, namely gene expression testing to determine immune response</p>	<p>Registered App Date: 12/13/2004 Reg Date: 11/19/2005</p> <p>Proof of Use Due: 11/19/2010 Renewal Date: 11/19/2015</p>
50661-24005.46	<p>XDX EXPRESSION DIAGNOSTIC AND DESIGN Serial No: 507932005 Reg. No: 537118</p>  <p>Expression Diagnostics, Inc. *</p>	Switzerland	<p>Class: 5 Biological chemical diagnostic test kits consisting of preparations for clinical or medical laboratory use, namely, for use in analysis of gene expression, genetics, single nucleotide polymorphism, haplotypes, proteins and biological samples, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug responses; diagnostic medical reagents, chemicals and solid matrix materials for biological clinical or medical laboratory use for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases, developmental disorders and cancer</p> <p>Class: 42 Chemical analysis of gene expression to determine immune response</p> <p>Class: 44 Diagnostic services, namely gene expression testing to determine immune response</p>	<p>Registered App Date: 2/1/2005 Reg Date: 9/13/2005</p> <p>Renewal Date: 2/1/2015</p>
50661-24008.00	<p>XDX Serial No: 78/516,406 Reg. No: 3,437,631</p> <p>XDX, Inc.</p>	United States	<p>Class: 5 Biological chemical test kits for medical laboratory use in analysis of gene expression in inflammatory and cardiovascular diseases and disorders</p>	<p>Registered App Date: 11/12/2004 Reg Date: 5/27/2008</p> <p>8&15 Due Date: 5/27/2014</p>
50661-24008.01	<p>XDX Serial No: 78/977,275 Reg. No: 3,160,957</p> <p>XDX, Inc.</p>	United States	<p>Class: 44 Medical diagnostic services, namely, gene expression testing to determine immune response</p>	<p>Registered App Date: 11/12/2004 Reg Date: 10/17/2006</p> <p>8&15 Due Date: 10/17/2012</p>
50661-24008.40	<p>XDX</p>	Australia	<p>Class: 5</p>	<p>Registered</p>

* Change of name to XDX, Inc. has not been recorded in this country yet. Awaiting client's instructions to proceed with recordal.

50661-24008.43	<p>Serial No: 1053814 Reg. No: 1053814</p> <p>Expression Diagnostics, Inc. *</p>	Canada	<p>Biological chemical diagnostic test kits for clinical or medical laboratory use, namely, for use in analysis of gene expression, genetics, single nucleotide polymorphism, haplotypes, proteins, and biological samples, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug responses; diagnostic medical reagents, chemicals and solid matrix materials for biological, clinical or medical laboratory use for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases, developmental disorders and cancer</p> <p>Class: 42 Diagnostic services, namely gene expression testing to determine immune response</p>	<p>App Date: 5/5/2005 Reg Date: 9/5/2005</p> <p>Proof of Use Due: 5/5/2010 Renewal Date: 5/5/2015</p>
50661-24008.44	<p>XDX Serial No: 1256696 Reg. No:</p> <p>Expression Diagnostics, Inc. *</p>	Europe *	<p>Goods: Biological chemical diagnostic test kits for clinical or medical laboratory use, namely, for use in analysis of gene expression, genetics, single nucleotide polymorphism, haplotypes, proteins, and biological samples, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug responses; diagnostic medical reagents, chemicals and solid matrix materials for biological, clinical or medical laboratory use for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases, developmental disorders and cancer</p> <p>Services: Diagnostic services, namely gene expression testing to determine immune response</p>	<p>Filed</p> <p>App Date: 5/5/2005 Allowed 10/7/2005</p> <p>Use Declaration/Reg Fees Due: 11/4/2009</p>
50661-24008.45	<p>XDX Serial No: 004439253 Reg. No: 004439253</p> <p>XDX, Inc.</p>	Japan	<p>Class: 5 Biological chemical diagnostic test kits for clinical or medical laboratory use, namely, for use in analysis of gene expression, genetics, single nucleotide polymorphism, haplotypes, proteins, and biological samples, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug responses; diagnostic medical reagents, chemicals and solid matrix materials for biological, clinical or medical laboratory use for use in diagnosing inflammatory, infectious, central nervous system, cardiovascular, neurological, endocrine, autoimmune and genetic diseases, developmental disorders and cancer</p> <p>Class: 42 Diagnostic services, namely gene expression testing to determine immune response</p>	<p>Registered</p> <p>App Date: 5/10/2005 Reg Date: 5/24/2006</p> <p>Renewal Date: 5/10/2015</p>
50661-24008.44	<p>XDX Serial No: 200540190 Reg. No: 4965981</p>	Japan	<p>Class: 5 Reagent kits for diagnostic tests consisting of chemicals, machines, parts and the like for use in analysis of gene expression, genetics, single nucleotide polymorphism, proteins, and biological samples, for use in analysis of haplotypes, for use in detecting diseases, for use in determining the progression of diseases, and for use in determining drug responses; diagnostic reagents sold or</p>	<p>Registered</p> <p>App Date: 5/9/2005 Reg Date: 6/30/2006</p> <p>Renewal Date: 6/30/2016</p>

* Change of name to XDX, Inc. has not been recorded in this country yet. Awaiting client's instructions to proceed with recordal.

* European Community Trademark Countries: Austria, Benelux (Belgium, The Netherlands & Luxembourg), Bulgaria, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Portugal, Romania, Spain, Sweden, United Kingdom, Cyprus, The Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Slovakia, and Slovenia.

SF-2732180

SCHEDULE C

COPYRIGHTS

None